Intuitive Surgical has delivered ten consecutive quarters of double-digit revenue growth, most recently 21.7% YoY in 2026Q3, supported by gross margin expansion of roughly 370 basis points from the 64.7% trough in 2025Q1 to 68.4% and a structurally unlevered balance sheet with zero debt across eight of ten quarters.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth remains durable at 21.7% in 2026Q3 with gross margin at 68.4%, but the 78% sequential SG&A spike to $1.1 billion drove operating margin down to 19.4% from 33.6%, appearing anomalous and warranting further investigation.
Analysts have a consensus rating of 'Strong Buy' with a median price target of $580.00, indicating a potential upside of 27.8%.
Management raised the 2026 procedure growth outlook to 13.5%-15.5%, supported by increased utilization across platforms.
Approximately 75% of ISRG's revenue comes from recurring sources, providing a stable and high-margin revenue stream.
ISRG trades at a high P/E ratio of around 55-58, with some analysts suggesting it could be overvalued by 30.2%.
Procedure growth is projected to slow to 13.5%-15.5% in 2026, down from 18% in 2025.
Factors like tariffs and pricing pressures in China could negatively impact revenue.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 20, 2026 | $3.00+13.2% vs $2.65 | $3.0B+4.9% vs $2.9B |
Q3 2026 Jul 16, 2026 | $2.80+11.6% vs $2.51 | $2.9B+2.4% vs $2.8B |
Q2 2026 Apr 21, 2026 | $2.80+11.6% vs $2.51 | $2.8B+5.8% vs $2.6B |
Q1 2026 Jan 22, 2026 | $2.53+11.5% vs $2.27 | $2.9B+3.7% vs $2.8B |
Hims & Hers Health is leveraging a high-growth, subscription-based digital platform to provide personalized treatments for weight loss and sexual health. Intuitive Surgical maintains a dominant market position with a massive installed base of robotic-assisted surgical systems and high net margins.
Intuitive Surgical (ISRG) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Integrity Alliance LLC. grew its stake in shares of Intuitive Surgical, Inc. (NASDAQ: ISRG) by 68.3% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,775 shares of the medical equipment provider's stock after acquiring an additional 1,126 shares
Intuitive Surgical's ISRG third-quarter 2026 system placements reflect continued demand for robotic-assisted surgery, although the increase does not clearly signal a broad-based acceleration in hospital capital spending. Da Vinci placements rose 28% year over year to 546 systems from 427, while net placements — which expand the installed base — grew 40%.
Benchmark ISRG against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Intuitive Surgical, Inc. (ISRG)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $452.80 | $159.96B | 57.53 | 20.51% | 28.38% | 16.57% | — | |
| $325.78 | $124.89B | 38.78 | 11.16% | 13.78% | 15.61% | 1.03% | |
| $101.80 | $130.7B | 27.29 | 8.43% | 13.93% | 10.51% | 2.78% | |
| $42.75 | $63.54B | 22.04 | 19.87% | 16.56% | 13.74% | — | |
| $105.59 | $20.43B | 29.74 | 7.2% | 9.48% | 6.36% | 0.91% | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — |
Intuitive Surgical, Inc. (ISRG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Intuitive Surgical, Inc. (ISRG) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 20, 2026·SEC
Jul 16, 2026·SEC
May 28, 2026·SEC
Get notified when ISRG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Intuitive Surgical, Inc. (ISRG) stock FAQ — growth, dividends, profitability & financials explained
Intuitive Surgical, Inc. (ISRG) reported $11.58B in revenue over the trailing twelve months. Revenue was $10.06B in fiscal year 2025. That is 98651% more than the $10.2M of fiscal year 1999.
Intuitive Surgical, Inc. (ISRG) grew revenue by 20.5% in fiscal year 2025, compared with the prior fiscal year.
Yes. Intuitive Surgical, Inc. (ISRG) earned $2.96B in net income over the trailing twelve months (a 25.5% net margin).
Intuitive Surgical, Inc. (ISRG) had a return on equity (ROE) of 16.6% in fiscal year 2025. That is above the market's typical 10-15%.
Intuitive Surgical, Inc. (ISRG) generated $3.60B in free cash flow over the trailing twelve months.
